| 1 |
Cardiac calcification in adult hemodialysis patients
Paolo Raggi, Amy Boulay, Scott Chasan-Taber et al. · Journal of the American College of Cardiology
Open access |
Feb 2002 |
1,130 |
| 2 |
Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663
Margaret van Heek, Constance Farley, Douglas S. Compton et al. · British Journal of Pharmacology
Open access |
Apr 2000 |
329 |
| 3 |
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone
Eduardo A. Slatopolsky, Steven K. Burke, Maureen A. Dillon · Kidney International
Open access |
1999 |
304 |
| 4 |
Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation
Driss El Kebir, Per Gjorstrup, János G. Filep · Proceedings of the National Academy of Sciences
Open access |
27 Aug 2012 |
285 |
| 5 |
A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients
Anthony J. Bleyer, Steven K. Burke, Maureen A. Dillon et al. · American Journal of Kidney Diseases
|
Apr 1999 |
277 |
| 6 |
Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure
Glenn Matthew Chertow, Steven K. Burke, J. Michael Lazarus et al. · American Journal of Kidney Diseases
|
1997 |
249 |
| 7 |
Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia
Howard H Knapp, Helmut G. Schrott, Patrick Ma et al. · The American Journal of Medicine
|
Apr 2001 |
203 |
| 8 |
Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats
Kyoko Saito Katsumata, Kenichiro Kusano, Michinori Hirata et al. · Kidney International
Open access |
8 Jul 2003 |
164 |
| 9 |
Structural genomics of protein phosphatases
Steven C. Almo et al. · Journal of Structural and Functional Genomics
Open access |
Sep 2007 |
162 |
| 10 |
Outcome of a Workshop on Applications of Protein Models in Biomedical Research
Torsten F. Schwede et al. · Structure
Open access |
Feb 2009 |
154 |
| 11 |
Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia
Mario Gennaro Cozzolino, Mark E. Staniforth, Helen Liapis et al. · Kidney International
Open access |
15 Oct 2003 |
144 |
| 12 |
Effectiveness of Colesevelam Hydrochloride in Decreasing LDL Cholesterol in Patients With Primary Hypercholesterolemia: A 24-Week Randomized Controlled Trial
William Insull, Phillip D. Toth, William S. Mullican et al. · Mayo Clinic Proceedings
|
Oct 2001 |
140 |
| 13 |
Controlling Herpes Simplex Virus-Induced Ocular Inflammatory Lesions with the Lipid-Derived Mediator Resolvin E1
Naveen K. Rajasagi, Pradeep B. J. Reddy, Amol S. Suryawanshi et al. · The Journal of Immunology
Open access |
28 Dec 2010 |
137 |
| 14 |
RnaGel(R), a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers
Steven K. Burke, Eduardo Slatopolsky, Dennis Goldberg · Nephrology Dialysis Transplantation
|
Aug 1997 |
128 |
| 15 |
The Effects of Sevelamer Hydrochloride and Calcium Carbonate on Kidney Calcification in Uremic Rats
Mario Gennaro Cozzolino, Adriana Dusso, Helen Liapis et al. · Journal of the American Society of Nephrology
Open access |
Sep 2002 |
117 |
| 16 |
The Effects of Sevelamer and Calcium Acetate on Proxies of Atherosclerotic and Arteriosclerotic Vascular Disease in Hemodialysis Patients
Glenn Matthew Chertow, Paolo Raggi, James T. McCarthy et al. · American Journal of Nephrology
|
2003 |
108 |
| 17 |
Effect of RenaGel(R), a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients
Dennis Goldberg · Nephrology Dialysis Transplantation
|
Sep 1998 |
107 |
| 18 |
Low‐dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low‐density lipoprotein cholesterol in patients with primary hypercholesterolemia
Michael H. Davidson, Phillip D. Toth, Stuart R. Weiss et al. · Clinical Cardiology
Open access |
Jun 2001 |
103 |
| 19 |
Drug Interactions with Colesevelam Hydrochloride, a Novel, Potent Lipid-Lowering Agent
Joanne M. Donovan, Daria Stypinski, Mark R. Stiles et al. · Cardiovascular Drugs and Therapy
|
Dec 2000 |
93 |
| 20 |
Effects of Bedtime Very Low Dose Cyclobenzaprine on Symptoms and Sleep Physiology in Patients with Fibromyalgia Syndrome: A Double-blind Randomized Placebo-controlled Study
Harvey Moldofsky, HERBERT W. HARRIS, W. Tad Archambault et al. · The Journal of Rheumatology
Open access |
Sep 2011 |
92 |
| 21 |
GT160-246, a Toxin Binding Polymer for Treatment of Clostridium difficile Colitis
Caroline B. Kurtz, E. Pat Cannon, Alex Brezzani et al. · Antimicrobial Agents and Chemotherapy
Open access |
Aug 2001 |
88 |
| 22 |
Resolvin E1 (RX-10001) Reduces Corneal Epithelial Barrier Disruption and Protects Against Goblet Cell Loss in a Murine Model of Dry Eye
Cintia Sade de Paiva, C. Schwartz, Per Gjorstrup et al. · Cornea
|
18 Jan 2012 |
84 |
| 23 |
Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study
Vlad Dzavik et al. · European Heart Journal
|
26 Apr 2007 |
79 |
| 24 |
Effect of RenaGel(R), a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats
David P. Rosenbaum, Stephen R Holmes-Farley, W. Harry Mandeville et al. · Nephrology Dialysis Transplantation
|
May 1997 |
74 |
| 25 |
Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids
Daniel K. Crawford, Jasper Mullenders, Johanna Pott et al. · Journal of Cystic Fibrosis
Open access |
6 Feb 2021 |
73 |
| 26 |
Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers
Andi Leubitz, Anat Frydman‐Marom, Neal Sharpe et al. · Clinical Pharmacology in Drug Development
Open access |
16 Jan 2019 |
72 |
| 27 |
The omega-3 fatty acid-derived neuroprotectin D1 limits hippocampal hyperexcitability and seizure susceptibility in kindling epileptogenesis
Alberto E. Musto, Per Gjorstrup, Nicolas Guillermo Bazan · Epilepsia
Open access |
13 May 2011 |
72 |
| 28 |
The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat
Yusuke Tomita, Min-Jung Lee, Sunmin Lee et al. · OncoImmunology
Open access |
31 Aug 2016 |
71 |
| 29 |
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4
Yan Zang, Sufi Mary Thomas, Elena T. Chan et al. · Autophagy
Open access |
20 Sep 2012 |
69 |
| 30 |
Therapeutic uses of antioxidant liposomes
William L. Stone, Milton G. Smith · Molecular Biotechnology
Open access |
Jul 2004 |
65 |
| 31 |
Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment
Vijayabhaskar Veeravalli, Ranjeet Prasad Dash, Jennifer A. Thomas et al. · Drug Safety
|
4 May 2020 |
63 |
| 32 |
ELX-02 Generates Protein via Premature Stop Codon Read-Through without Inducing Native Stop Codon Read-Through Proteins
Daniel K. Crawford, Iris Alroy, Neal Sharpe et al. · Journal of Pharmacology and Experimental Therapeutics
Open access |
6 May 2020 |
56 |
| 33 |
Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study
Patrick B. Deegan, Özlem Göker-Alpan, Tarekegn Geberhiwot et al. · Molecular Genetics and Metabolism
Open access |
8 Nov 2022 |
55 |
| 34 |
A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome
Raffaele Badolato et al. · Blood
Open access |
21 Apr 2024 |
54 |
| 35 |
Sevelamer, a Phosphate-Binding Polymer, is a Non-Absorbed Compound
Melissa A. Plone, John S. Petersen, David P. Rosenbaum et al. · Clinical Pharmacokinetics
|
2002 |
54 |
| 36 |
Development and evaluation of a multimodal marker of major depressive disorder
Jie Yang et al. · Human Brain Mapping
Open access |
16 Aug 2018 |
50 |
| 37 |
Efficacy and Safety of Sublingual Cyclobenzaprine for the Treatment of Fibromyalgia: Results From a Randomized, Double‐Blind, Placebo‐Controlled Trial
Seth M. Lederman, Lesley M. Arnold, Ben J Vaughn et al. · Arthritis Care & Research
Open access |
11 May 2023 |
48 |
| 38 |
Anti-microRNA-21 Therapy on Top of ACE Inhibition Delays Renal Failure in Alport Syndrome Mouse Models
Diana M. Rubel, Joseph Boulanger, Florin L. Craciun et al. · Cells
Open access |
9 Feb 2022 |
44 |
| 39 |
Genetics of cystogenesis in base-edited human organoids reveal therapeutic strategies for polycystic kidney disease
Courtney E. Vishy, Chardai J. Thomas, Thomas L. Vincent et al. · Cell stem cell
Open access |
Apr 2024 |
42 |
| 40 |
Novel Cholesterol Lowering Polymeric Drugs Obtained by Molecular Imprinting
Chad C. Huval, Mathew J. Bailey, William H. Braunlin et al. · Macromolecules
|
14 Feb 2001 |
42 |
| 41 |
Vacuuming the Periplasm
Olga Lomovskaya, Maxim M. Totrov · Journal of Bacteriology
Open access |
2 Mar 2005 |
40 |
| 42 |
Polymeric metal complex catalyzed enantioselective epoxidation of olefins
Pradeep K. Dhal, Binod B. De, Swaminathan Sivaram · Journal of Molecular Catalysis A Chemical
|
Dec 2001 |
40 |
| 43 |
A Randomized, Double‐Blind, Placebo‐Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX‐02 in Healthy Subjects
Andi Leubitz, Frédéric P. Vanhoutte, Ming‐yi Hu et al. · Clinical Pharmacology in Drug Development
Open access |
19 Jan 2021 |
36 |
| 44 |
Sevelamer Hydrochloride (Renagel®), a Nonabsorbed Phosphate‐Binding Polymer, Does Not Interfere with Digoxin or Warfarin Pharmacokinetics
Steven K. Burke, Naseem S. Amin, Carlo Incerti et al. · The Journal of Clinical Pharmacology
|
Feb 2001 |
35 |
| 45 |
The novel aminoglycoside, ELX-02, permits CTNSW138X translational read-through and restores lysosomal cystine efflux in cystinosis
Emma J. Brasell, Lee Lee Chu, Murielle M. Akpa et al. · PLoS ONE
Open access |
4 Dec 2019 |
34 |
| 46 |
Studies of cholesterol and bile acid metabolism, and early atherogenesis in hamsters fed GT16-239, a novel bile acid sequestrant (BAS)
Thomas A. Wilson, Robert J. Nicolosi, Eugene J. Rogers et al. · Atherosclerosis
|
Oct 1998 |
34 |
| 47 |
Neuronal Nitric Oxide Synthase Contributes to the Regulation of Hematopoiesis
Peter A. Krasnov, Tatyana V. Michurina, Michael A. Packer et al. · Molecular Medicine
Open access |
25 Feb 2008 |
32 |
| 48 |
Sevelamer Hydrochloride (Renagel®), a Phosphate‐Binding Polymer, Does Not Alter the Pharmacokinetics of Two Commonly Used Antihypertensives in Healthy Volunteers
Steven K. Burke, Naseem S. Amin, Carlo Incerti et al. · The Journal of Clinical Pharmacology
|
Feb 2001 |
27 |
| 49 |
Absorption, Distribution and Excretion of GT31-104, a Novel Bile Acid Sequestrant, in Rats and Dogs After Acute and Subchronic Administration
David P. Rosenbaum, John S. Petersen, Sylvie Ducharme et al. · Journal of Pharmaceutical Sciences
|
May 1997 |
27 |
| 50 |
Determination of the binding parameter constants of Renagel® capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography
Ronald A. Swearingen, Xi Chen, John S. Petersen et al. · Journal of Pharmaceutical and Biomedical Analysis
|
Jun 2002 |
27 |